01176nas a2200337   4500000000100000008004100001260001300042653003000055653002100085653001100106653001400117653002300131653001200154653002500166653002200191653002500213653001600238653003200254100001100286700001400297700001700311700001200328700001400340700001600354700001300370245004500383300001300428490000600441520037700447022001400824       2002                            d  c2002 Sep10aDrug Therapy, Combination10aErythema Nodosum10aHumans10aIncidence10aLeprostatic Agents10aleprosy10aLeprosy, lepromatous10aModels, Molecular10aMycobacterium leprae10aThalidomide10aTumor Necrosis Factor-alpha1 aTeo SK1 aResztak K1 aScheffler MA1 aKook KA1 aZeldis JB1 aStirling DI1 aThomas S00aThalidomide in the treatment of leprosy.  a1193-2020 v43 a<p>Leprosy is a chronic infection of the skin and nerves caused by Mycobacterium leprae. Erythema nodosum leprosum (ENL) is a reactive state in lepromatous leprosy. Thalidomide has been used to treat ENL since the 1960s. One of its mechanisms of action is anti-inflammatory through selective inhibition of the pro-inflammatory cytokine TNF-alpha produced by monocytes.</p>  a1286-4579